

Redesigning antibodies. Treating with RNA. Synthesizing DNA from scratch.

7 Japanese companies and technologies — from early R&D to clinical stage — in antibody discovery, RNA & artificial nucleic acid therapeutics, and AI-powered cancer diagnostics, live at CIC Cambridge.

Therapeutics

AI Diagnostics

RNA Medicine

Antibody Discovery

Where Deal Flow Meets Deep Tech

FOR

VCs & Investors

Meet Japanese biotech companies from early to clinical stages including a miRNA platform, hard to target antibody discovery, and a non-coding RNA platform — all pre-screened through Hiroshima University's startup selection process.

Pharma & Medtech Corporates

Engage with 3 Japanese biotechs and 4 university research platforms, with IP structured for licensing or co-development discussions.

RESEARCH TRACKS

- | | |
|----|---|
| 01 | miRNA Therapeutics — PURMX Therapeutics |
| 02 | Antibody Discovery — iBody Inc. |
| 03 | Target Discovery — Cloverna Inc. |
| 04 | Host-free DNA Synthesis — Hiroshima University |
| 05 | Artificial Nucleic Acid Therapeutics for Multiple Myeloma — Tohoku University |
| 06 | AI-Powered Diagnostics for Pancreatic Cancer — Nagoya University |
| 07 | Peptide Therapeutics for Alzheimer's Disease — OIST |

Join us at Venture Cafe Cambridge's Thursday Gathering!

Thursday, September 17, 2026. 6–7 PM

Venture Cafe/CIC Cambridge 5F, Havana (1 Broadway, Cambridge)

Contact: japandesk@cic.com

